UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 2, 2016
SHIRE PLC
(Exact name of registrant as specified in its charter)
Jersey, Channel Islands | 0-29630 | 98-0601486 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
5 Riverwalk, Citywest Business Campus, Dublin
24, Republic of Ireland
(Address of principal executive offices)
Registrant’s telephone number, including area code: +353 1 429 7700
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01. Entry into a Material Definitive Agreement.
RCF and Term Facility Amendments
On December 12, 2014, Shire plc, a Jersey public company (“ Shire ”), entered into a $2,100 million revolving credit facilities agreement with a number of financial institutions (the “ RCF ”), as amended on November 25, 2015. See Shire’s Form 8-K dated November 30, 2015 for details.
On November 2, 2015, Shire entered into a term facilities agreement comprising three credit facilities with a number of financial institutions (the “ Term Facility ”). See Shire’s Form 8-K dated November 2, 2015 for details.
On January 15, 2016, pursuant to the terms and conditions contained therein, Shire Acquisitions Investments Ireland DAC (“ SAIIDAC ”), a wholly-owned subsidiary of Shire, acceded as an additional borrower and additional guarantor to the Term Facility and as additional guarantor to the RCF. See Shire’s Form 8-K dated January 22, 2016 for details.
Extension of the RCF
On December 1, 2016, the termination date of the RCF was extended, in accordance with its terms, by one year from December 12, 2020 to December 12, 2021 with respect to all drawn and undrawn commitments under the RCF.
Amendment to the RCF and Term Facility
On December 1, 2016, the terms of each of the RCF and Term Facility were amended to update certain of the schedules contained therein relating to existing security, existing loans and existing financial indebtedness of certain Shire subsidiaries, primarily to permit certain inherited subsidiary-level security, loans and other financial indebtedness to subsist.
Accession of Baxalta to the RCF and Term Facility
On December 1, 2016, Baxalta Incorporated (“ Baxalta ”), a wholly-owned subsidiary of Shire, acceded as additional guarantor to each of the RCF and Term Facility pursuant to the terms and conditions contained therein.
The foregoing description of the amendments to each of the RCF and Term Facility is a general description; it does not purport to be complete and is qualified in its entirety by the full text of the amendments attached as Exhibits 99.1, 99.2, 99.3 and 99.4.
Guarantee by Baxalta of the SAIIDAC Notes
On September 23, 2016, SAIIDAC issued $12,100 million aggregate principal amount of senior notes, fully and unconditionally guaranteed by Shire (the “ SAIIDAC Notes ”), pursuant to an indenture dated September 23, 2016 (as amended, supplemented or modified, the “ Indenture ”) by and between Shire, SAIIDAC and Deutsche Bank Trust Company Americas as Trustee, and a first supplemental indenture thereto dated September 23, 2016. See Shire’s Form 8-K dated September 23, 2016 for details.
Guarantee by Baxalta of the SAIIDAC Notes
Pursuant to the terms of the Indenture, Baxalta has entered into a supplemental indenture to the Indenture, dated December 1, 2016 (the “ Second Supplemental Indenture ”), under which Baxalta has fully and unconditionally guaranteed the SAIIDAC Notes, subject to the terms and conditions stated therein. A copy of the Second Supplemental Indenture is filed as Exhibit 4.1 hereto and is incorporated by reference herein.
The foregoing description of the Second Supplemental Indenture is a general description; it does not purport to be complete and is qualified in its entirety by the full text of the agreement attached as Exhibit 4.1.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits. The following exhibits are filed herewith:
4.1 Second Supplemental Indenture, dated as of December 1, 2016, to the Indenture dated as of September 23, 2016, among SAIIDAC, Shire, as guarantor, Baxalta, as guarantor, and Deutsche Bank Trust Company Americas, as trustee.
99.1 Consent Request with respect to the RCF dated November 8, 2016.
99.2 Consent Request Approval Notice with respect to the RCF dated December 1, 2016.
99.3 Consent Request with respect to the Term Facility dated November 8, 2016.
99.4 Consent Request Approval Notice with respect to the Term Facility dated December 1, 2016.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Shire plc | |||
By: | /s/ W R Mordan | ||
Name: | Bill Mordan | ||
Title: | Company Secretary |
Date: December 2, 2016
EXHIBIT INDEX
Exhibit No. |
Description |
|
4.1 | Second Supplemental Indenture, dated as of December 1, 2016, to the Indenture dated as of September 23, 2016, among SAIIDAC, Shire, as guarantor, Baxalta, as guarantor, and Deutsche Bank Trust Company Americas, as trustee. | |
99.1 | Consent Request with respect to the RCF dated November 8, 2016. | |
99.2 | Consent Request Approval Notice with respect to the RCF dated December 1, 2016. | |
99.3 | Consent Request with respect to the Term Facility dated November 8, 2016. | |
99.4 | Consent Request Approval Notice with respect to the Term Facility dated December 1, 2016. |
Exhibit 4.1
SHIRE ACQUISITIONS INVESTMENTS IRELAND
DESIGNATED ACTIVITY COMPANY
as Issuer
SHIRE PLC
as Guarantor
BAXALTA INCORPORATED
as Subsidiary Guarantor
AND
DEUTSCHE BANK TRUST COMPANY AMERICAS
as Trustee
_________________
SECOND SUPPLEMENTAL INDENTURE
Dated as of December 1, 2016
to the
INDENTURE
Dated as of September 23, 2016
as supplemented by the
FIRST SUPPLEMENTAL INDENTURE
Dated as of September 23, 2016
_________________
TABLE OF CONTENTS
_________________
Page
Article 1 Definitions | |
Section 1.01. Relation to Indenture | 2 |
Section 1.02. Definition of Terms | 2 |
Article 2 Baxalta Guarantee | |
Section 2.01. Baxalta Guarantee | 3 |
Section 2.02. Subrogation; Ranking | 3 |
Section 2.03. Limitation on Liability | 4 |
Section 2.04. Successors and Assigns | 4 |
Section 2.05. No Waiver | 4 |
Section 2.06. Release of Baxalta Guarantee | 4 |
Section 2.07. Modification of Indenture | 5 |
Article 3 Miscellaneous | |
Section 3.01. Ratification of Indenture | 5 |
Section 3.02. Transfer of Interest | 5 |
Section 3.03. Notices, Etc., to Baxalta | 5 |
Section 3.04. No Recourse Against Others | 6 |
Section 3.05. Trustee Not Responsible for Recitals | 6 |
Section 3.06. Governing Law | 6 |
Section 3.07. Waiver of Trial by Jury | 6 |
Section 3.08. Table of Contents, Headings, etc | 6 |
Section 3.09. Execution in Counterparts | 6 |
Section 3.10. Separability; Benefits | 6 |
THIS SECOND SUPPLEMENTAL INDENTURE (this “ Second Supplemental Indenture ”), dated as of December 1, 2016, is among SHIRE ACQUISITIONS INVESTMENTS IRELAND DAC, an Irish designated activity company (the “ Company ”), as Issuer, SHIRE PLC, a Jersey public limited company and parent of the Company (“ Shire ”), as Guarantor, BAXALTA INCORPORATED, a Delaware corporation and wholly-owned subsidiary of Shire (“ Baxalta ”), as Subsidiary Guarantor, and DEUTSCHE BANK TRUST COMPANY AMERICAS (the “ Trustee ”), as Trustee.
R E C I T A L S
WHEREAS, the Company has heretofore executed and delivered to the Trustee an Indenture, dated as of September 23, 2016, among the Company, Shire and the Trustee (the “ Base Indenture ”), for the issuance from time to time of series of Securities of the Company (“ Securities ”), as supplemented by a supplemental indenture thereto, dated as of September 23, 2016, among the Company, Shire and the Trustee (the “ First Supplemental Indenture ”), providing for the establishment of four series of Securities pursuant to Section 2.02 of the Base Indenture, known as the (i) 1.900% Senior Notes due 2019 (the “ 2019 Notes ”), (ii) 2.400% Senior Notes due 2021 (the “ 2021 Notes ”), (iii) 2.875% Senior Notes due 2023 (the “ 2023 Notes ”) and (iv) the 3.200% Senior Notes due 2026 (the “ 2026 Notes ” and, together with the 2019 Notes, the 2021 Notes and the 2023 Notes, the “ Notes ”), the form, substance, terms, provisions and conditions of which were set forth in the Base Indenture and the First Supplemental Indenture (the Base Indenture, as amended, supplemented and modified by the First Supplemental Indenture or otherwise from time to time, shall be referred to herein as the “ Indenture ”);
WHEREAS, Section 10.01(j) of the Base Indenture provides for the Company, Shire and the Trustee from time to time and at any time, without the consent of the holders of the Securities of any series, to enter into an indenture or indentures supplemental to the Base Indenture to add guarantees with respect to the Securities of any series or to secure the Securities of any series;
WHEREAS, Section 6.01 of the First Supplemental Indenture provides that, if Baxalta becomes a guarantor of any Credit Facility (as defined therein), then within 10 Business Days (as defined therein) of such event, the Company shall cause Baxalta to enter into a supplemental indenture to the Base Indenture pursuant to which Baxalta shall agree to fully and unconditionally guarantee on a direct, unsecured basis the due and punctual payment of the principal of, and any premium and interest on, the Notes and all other amounts, if any, under the Indenture in respect of the Notes when and as such principal, premium, if any, interest and other amounts, if any, become due and payable, whether at maturity or otherwise;
WHEREAS, pursuant to Section 6.01 of the First Supplemental Indenture, Baxalta has agreed to execute and deliver to the Trustee this Second Supplemental Indenture pursuant to which Baxalta shall fully and unconditionally guarantee on a direct, unsecured basis the due and punctual payment of the principal of, and any premium and interest on, the Notes and all other amounts, if any, under the Indenture in respect of the Notes when and as such principal, premium, if any, interest and other amounts, if any, become due and payable, whether at maturity or otherwise on the terms and conditions set forth herein and in the Indenture;
WHEREAS, the Company has furnished the Trustee with an Officers’ Certificate and an Opinion of Counsel, provided for under Sections 10.05 and 15.07 of the Base Indenture, stating that the execution of this Second Supplemental Indenture complies with the requirements of the Indenture, is authorized or permitted by the Indenture, and that this Second Supplemental Indenture constitutes a legal, valid and binding obligation of the Company, Shire and Baxalta, subject to certain customary exceptions stated therein, and that all conditions precedent to the execution and delivery of this Second Supplemental Indenture have been complied with;
NOW, THEREFORE, in consideration of the covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:
Article
1
Definitions
Section 1.01. Relation to Indenture . This Second Supplemental Indenture constitutes an integral part of the Indenture.
Section 1.02. Definition of Terms . For all purposes of this Second Supplemental Indenture:
(a) Capitalized terms used herein without definition shall have the meanings set forth in the Base Indenture or the First Supplemental Indenture, as applicable;
(b) a term defined anywhere in this Second Supplemental Indenture has the same meaning throughout;
(c) the singular includes the plural and vice versa;
(d) headings are for convenience of reference only and do not affect interpretation;
(e) the following terms have the meanings given to them in this Section 1.02(e):
“ Baxalta Guarantee ” shall have the meaning set forth in Section 2.01.
“ Baxalta Guaranteed Obligations ” shall have the meaning set forth in Section 2.01.
“ Subsidiary Guarantor ” shall mean, with respect to the Notes of any series, Baxalta and any legal successor thereto.
The terms “ Base Indenture ,” “ Baxalta ,” “ Company ,” “ First Supplemental Indenture ,” “ Indenture ,” “ Notes ,” “ Second Supplemental Indenture ,” “ Securities ,” “ Shire ,” “ Trustee ,” “ 2019 Notes ,” “ 2021 Notes ,” “ 2023 Notes ” and “ 2026 Notes ” shall have the respective meanings set forth in the recitals to this Second Supplemental Indenture and the paragraph preceding such recitals.
2
Article
2
Baxalta Guarantee
Section 2.01. Baxalta Guarantee . Pursuant to the provisions of Section 6.01 of the First Supplemental Indenture, Baxalta, as primary obligor and not merely as surety, hereby fully and unconditionally guarantees on a direct, unsecured basis to each holder of the Notes of each series and to the Trustee, the Agents and their respective successors and assigns the due and punctual payment of the principal of, and any premium and interest on, the Notes and all other amounts, if any, under the Indenture in respect of the Notes when and as such principal, premium, if any, interest and other amounts, if any, become due and payable, whether at maturity or otherwise (all such obligations hereinafter collectively called the “ Baxalta Guaranteed Obligations ”) (such guarantee, the “ Baxalta Guarantee ”).
Baxalta waives all set-offs and counterclaims, notice of acceptance of the Baxalta Guarantee, diligence, presentment, demand of payment, filing of claims with a court in the event of merger or insolvency or bankruptcy of the Company, any right to require a proceeding filed first against the Company, protest or notice with respect to the Notes or the indebtedness evidenced thereby and all demands whatsoever.
The obligations of Baxalta hereunder shall not be affected by (a) the failure of any Noteholder, the Trustee or Agents to assert any claim or demand or to enforce any right or remedy against the Company, any other guarantor or any other Person under the Indenture, the Notes of any series or any other agreement or otherwise; (b) any extension or renewal of any obligation of the Company under the Indenture or any Note, by operation of law or otherwise; (c) any rescission, waiver, amendment or modification of any of the terms or provisions of the Indenture, the Notes of any series or any other agreement; or (d) any lack of validity or enforceability of the Indenture, the Notes or any other agreement or instrument relating thereto.
Baxalta further agrees that its Baxalta Guarantee herein constitutes a guarantee of payment when due (and not a guarantee of collection) and waives any right to require that any resort be had by any Noteholder, the Trustee or Agents to any security held for payment of the Baxalta Guaranteed Obligations.
Baxalta also agrees to pay any and all costs and expenses (including reasonable attorneys’ fees) incurred by the Trustee, the Agents or any Noteholder in enforcing any rights under this Article 2.
Section 2.02. Subrogation; Ranking .
(a) Baxalta shall be subrogated to all rights of the Trustee or the holders of any Notes against the Company in respect of any amounts paid to the Trustee or such holder by Baxalta pursuant to the provisions of the Baxalta Guarantee; provided , however , that Baxalta waives any right to enforce, or to receive any payments arising out of, or based upon, such right of subrogation until all Baxalta Guaranteed Obligations shall have been paid in full.
(b) Baxalta covenants and agrees that its obligation to make payments of the Baxalta Guaranteed Obligations hereunder constitutes a direct, unsecured obligation of Baxalta ranking
3
equally in right of payment with all existing and future unsecured and unsubordinated obligations of Baxalta and senior in right of payment to all future obligations of Baxalta that are expressly subordinated to the Baxalta Guaranteed Obligations.
Section 2.03. Limitation on Liability . Baxalta, and by its acceptance of the Baxalta Guarantee, each holder of Notes of each such series, hereby confirms that it is the intention of all such parties that the Baxalta Guarantee (a) does not constitute a fraudulent transfer or conveyance for purposes of any Federal, state or foreign bankruptcy, insolvency, receivership or similar law now or hereafter in effect, the Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act or any similar foreign, federal or state law to the extent applicable to the Baxalta Guarantee, and (b) does not result in a distribution to Noteholders not permitted under the applicable foreign or state law. Any term or provision of the Indenture to the contrary notwithstanding, the maximum aggregate amount of the obligations guaranteed hereunder by Baxalta shall not exceed the maximum amount that can be hereby guaranteed without rendering the Baxalta Guarantee voidable under applicable law relating to fraudulent conveyance or fraudulent transfer or similar laws affecting the rights of creditors generally.
Section 2.04. Successors and Assigns . Subject to Section 2.06 hereof, this Article 2 shall be binding upon Baxalta and its successors and assigns and shall inure to the benefit of the successors and assigns of the Trustee, the Agents and the Noteholders and, in the event of any transfer or assignment of rights by any Noteholders, the Trustee or the Agents, the rights and privileges conferred upon that party in the Indenture and in the Notes of the relevant series shall automatically extend to and be vested in such transferee or assignee, all subject to the terms and conditions of the Indenture.
Section 2.05. No Waiver . Neither a failure nor a delay on the part of either the Trustee, the Agents or the Noteholders in exercising any right, power or privilege under this Article 2 shall operate as a waiver thereof, nor shall a single or partial exercise thereof preclude any other or further exercise of any right, power or privilege. The rights, remedies and benefits of the Trustee, the Agents and the Noteholders herein expressly specified are cumulative and not exclusive of any other rights, remedies or benefits which either may have under this Article 2 at law, in equity, by statute or otherwise.
Section 2.06. Release of Baxalta Guarantee . The Baxalta Guarantee shall be automatically released with respect to a series of Notes and the Indenture with respect to such series of Notes:
(a) upon the release or termination of Baxalta’s guarantee with respect to all Credit Facilities such that, after such release or termination, Baxalta is no longer a guarantor of any Credit Facility;
(b) upon (i) the sale or other disposition (including by way of consolidation, merger, dissolution or otherwise) of the capital stock of Baxalta such that it is no longer a Subsidiary of Shire or (ii) the sale or other disposition of all or substantially all of the assets of Baxalta, in either such case in accordance with the terms of the Indenture;
4
(c) if the Company exercises its defeasance option with respect to such series of Notes pursuant to Sections 12.02 or 12.03 of the Base Indenture or if the Company’s obligations under the Indenture with respect to such series of Notes are satisfied and discharged in accordance with the terms of the Indenture; or
(d) otherwise upon payment in full of the Baxalta Guaranteed Obligations with respect to such series of Notes.
Section 2.07. Modification of Indenture . Notwithstanding anything to the contrary in the Indenture, the Company, Shire and Baxalta, together with the Trustee, may by supplemental indenture modify the terms of, or terminate, the Baxalta Guarantee with respect to one or more series of Notes with the consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of all series issued under the Indenture, including such series of Notes, affected by such modification or termination, voting as a single class. Notwithstanding the foregoing, holders of the Notes of any series shall vote as a separate class with respect to a modification or termination of the Baxalta Guarantee that affects only the Notes of such series, and the holders of other series of debt securities issued under the Indenture shall not have any voting rights with respect to such matters as they relate to the Notes of such series.
Article
3
Miscellaneous
Section 3.01. Ratification of Indenture . The Base Indenture, as supplemented by the First Supplemental Indenture and this Second Supplemental Indenture, is in all respects ratified and confirmed, and this Second Supplemental Indenture shall be deemed part of the Base Indenture, as supplemented by the First Supplemental Indenture, in the manner and to the extent herein and therein provided.
Section 3.02. Transfer of Interest . Subject to Section 2.06 hereof, the Baxalta Guarantee shall be binding upon Baxalta and its successors and assigns, and shall inure to the benefit of and be enforceable by any Holder of Notes, the Trustee, and by their respective successors, transferees and assigns, pursuant to the terms hereof. The Baxalta Guarantee shall not be deemed to create any right in, or to be in whole or in part for the benefit of, any other person.
Section 3.03. Notices, Etc., to Baxalta . Any request, demand, authorization, direction, notice, consent, waiver or other action of Holders or other document provided or permitted by the Indenture to be made upon, given or furnished to, or filed with, Baxalta by the Trustee or by any Holder shall be sufficient for every purpose hereunder (unless otherwise herein expressly provided) if in writing and mailed, first-class postage prepaid, or by any courier guaranteeing overnight delivery, to Baxalta addressed to the address last furnished in writing to the Trustee by Baxalta, or, if no such address has been furnished, to Attn: William R. Mordan, General Counsel, Shire plc, 5 Riverwalk, Citywest Business Campus, Dublin 24, Republic of Ireland. All requests and other communications shall be deemed to have been duly given three business days after being deposited in the mail if mailed postage prepaid; and on the next business day if timely delivered to an air courier guaranteeing overnight delivery.
5
Section 3.04. No Recourse Against Others . A director, officer, employee, stockholder, partner or other owner of Baxalta, as such, shall not have any liability for any obligations of Baxalta under this Second Supplemental Indenture, including the Baxalta Guarantee, or for any claim based on, in respect of or by reason of such obligations or their creation.
Section 3.05. Trustee Not Responsible for Recitals . The recitals herein contained are made by the Company, Shire or Baxalta, as applicable, and not by the Trustee, and the Trustee assumes no responsibility for the correctness thereof. The Trustee makes no representation as to the validity or sufficiency of this Second Supplemental Indenture.
Section 3.06. Governing Law . THIS SECOND SUPPLEMENTAL INDENTURE AND EACH NOTE, AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS SECOND SUPPLEMENTAL INDENTURE OR ANY NOTE, SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.
Section 3.07. Waiver of Trial by Jury . EACH OF THE COMPANY, BAXALTA, THE TRUSTEE, SHIRE AND EACH HOLDER OF NOTES, BY ITS ACCEPTANCE THEREOF, HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE NOTES OR THE TRANSACTIONS CONTEMPLATED HEREBY.
Section 3.08. Table of Contents, Headings, etc . The table of contents and the titles and headings of the articles and sections of this Second Supplemental Indenture have been inserted for convenience of reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof.
Section 3.09. Execution in Counterparts . This Second Supplemental Indenture may be executed in any number of counterparts, each of which shall be an original, but such counterparts shall together constitute but one and the same instrument. Signatures delivered by facsimile or in portable document format (.pdf) by email shall be deemed to be originals for all purposes hereunder.
Section 3.10. Separability; Benefits . In case any one or more of the provisions contained in this Second Supplemental Indenture or in the Notes shall for any reason be held to be invalid, illegal or unenforceable, in any respect, then, to the extent permitted by law, such invalidity, illegality or unenforceability of the remaining provisions shall not in any way be affected or impaired thereby. Nothing in this Second Supplemental Indenture or in the Notes, expressed or implied, shall give to any person, other than the parties hereto and their successors hereunder, and the holders of the Notes, any benefit or any legal or equitable right, remedy or claim under this Second Supplemental Indenture.
[ Signature Page Follows ]
6
IN WITNESS WHEREOF, the parties hereto have caused this Second Supplemental Indenture to be duly executed, as of the day and year first written above.
GIVEN under the common seal of SHIRE ACQUISITIONS INVESTMENTS IRELAND DAC and DELIVERED as a DEED : | ||
/s/ Michael Garry | ||
Name: Michael Garry | ||
Title: Director | ||
/s/ Vincent Dunne |
||
Name: Vincent Dunne | ||
Title: Director | ||
SHIRE PLC , as Guarantor |
||
By: | /s/ Jeffrey Poulton | |
Name: Jeffrey Poulton | ||
Title: Chief Financial Officer | ||
BAXALTA INCORPORATED , as Subsidiary Guarantor |
||
By: | /s/ John Miller | |
Name: John Miller | ||
Title: Director |
[ Signature page to Second Supplemental Indenture ]
IN WITNESS WHEREOF, the parties hereto have caused this Second Supplemental Indenture to be duly executed, as of the day and year first written above.
DEUTSCHE BANK TRUST COMPANY AMERICAS , not in its individual capacity but solely as Trustee, Security Registrar and Paying Agent |
||
By: Deutsche Bank National Trust Company | ||
By: | /s/ Chris Niesz | |
Name: Chris Niesz | ||
Title: Assistant Vice President | ||
By: | /s/ Irina Golovashchuk | |
Name: Irina Golovashchuk | ||
Title: Vice President |
[ Signature page to Second Supplemental Indenture ]
Exhibit 99.1
5 Riverwalk Citywest Business Campus Dublin 24
Ireland
|
|
EMEA Loans Agency
Barclays Bank PLC
5 The North Colonnade
Canary Wharf
London E14 4BB
For the attention of: Norman Chan
8 November 2016
CONSENT REQUEST
US$2,100,000,000 Revolving Credit Facilities Agreement dated 12 December 2014
1. | Introduction |
1.1 | We refer to the US$2,100,000,000 revolving credit facilities agreement dated 12 December 2014 (as amended on 25 November 2015) between, among others, Shire plc (the “ Company ”) as an Original Borrower and an Original Guarantor and Barclays Bank PLC as Facility Agent (the “ Facilities Agreement ”). |
1.2 | Save as otherwise defined in this letter, terms and expressions defined in the Facilities Agreement shall have the same meanings when used in this letter and references to Clauses in this letter are references to the relevant clauses of the Facilities Agreement. |
1.3 | We are writing to you in your capacity as Facility Agent pursuant to and in accordance with Clause 42.1 ( Required consents ) to request that the Majority Lenders consent to the amendments described in paragraph 2 of this letter, such amendments to become effective immediately upon the Facility Agent delivering to the Company a signed notice in the form set out in Appendix 1 ( Form of Request Approval Notice ) (a “ Request Approval Notice ”) and the Obligors accepting such Request Approval Notice by signing, dating, and returning a copy thereof to the Facility Agent. |
2. | Requests |
We hereby request that:
(A) | Schedule 9 of the Facilities Agreement be amended to reflect the changes shown in the redline set out in Appendix 2 ( Schedule 9 Existing Security ); |
(B) | Schedule 10 of the Facilities Agreement be amended to reflect the changes shown in the redline set out in Appendix 3 ( Schedule 10 Existing Loans ); and |
(C) | Schedule 11 of the Facilities Agreement be amended to reflect the changes shown in the redline set out in Appendix 4 ( Schedule 11 Existing Financial Indebtedness ), |
(together the “ Requested Amendments ”).
Shire plc
Incorporated and registered in Jersey No. 99854
Registered Office: 22 Grenville Street, St Helier, Jersey JE4 8PX
Correspondence Address: 5 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
3. | Timing of consents |
3.1 | A response is requested by 5:00 pm on 16 November 2016 (the “ Request Deadline ”). |
If, by the Request Deadline, Majority Lenders have provided their consent to the Requested Amendments the Facility Agent shall deliver to the Company a Request Approval Notice.
3.2 | If, by the Request Deadline, the Facility Agent has not delivered to the Company a Request Approval Notice, the Company reserves the right to extend the Request Deadline or, after the expiry of the Request Deadline (whether or not extended), to re-open this consent request (and, if necessary or desirable, amend the content of this consent request) and set a new deadline. |
4. | Miscellaneous |
By providing a Request Approval Notice, you agree in your capacity as Facility Agent that this letter is a Finance Document for the purposes of the Facilities Agreement.
5. | Governing Law and Enforcement |
The provisions of Clause 46 ( Governing law ) and Clause 47 ( Enforcement ) are incorporated into this letter as though they were set out in full, except that references to the Facilities Agreement are to be construed as references to this letter.
Yours faithfully
/s/ Jeffrey Poulton
………………………………
for and on behalf of
Shire plc
Exhibit 99.2
|
5 The North Colonnade
Canary Wharf
London E14 4BB
United Kingdom
Tel +44 (0)20 7623 2323
barclays.com
|
PRIVATE AND CONFIDENTIAL
Shire plc (the “
Company
”)
5 Riverwalk
Citywest Business Campus
Dublin 24
Ireland
For the attention of: Thomas Greene
21 November 2016
SHIRE PLC – CONSENT REQUEST
1. | We refer to: |
(A) | the US$2,100,000,000 revolving credit facilities agreement dated 12 December 2014 (as amended on 25 November 2015) between, among others, Shire plc as an Original Borrower and an Original Guarantor and Barclays Bank PLC as Facility Agent (the “ Facilities Agreement ”); and |
(B) | your letter to us dated 8 November 2016 in which you requested that the Majority Lenders consent to certain amendments to schedule 9 ( Existing Security ) , to schedule 10 ( Existing Loans ) and to schedule 11 ( Existing Financial Indebtedness ) of the Facilities Agreement (the “ Consent Request ”). |
2. | Unless otherwise defined, terms and expressions defined in the Facilities Agreement or in the Consent Request shall have the same meanings when used in this letter and references to Clauses in this letter are references to the relevant clauses of the Facilities Agreement. |
3. | We confirm that we have received the consent of the Majority Lenders to the Requested Amendments and consequently that the Requested Amendments shall, provided that you and the other Obligor sign, date and return to us a copy of this letter in accordance with paragraph 1.3 of the Consent Request become effective immediately and automatically, and from that date the Facilities Agreement and the Consent Request shall be read and construed as one document. |
4. | Please confirm your agreement to the terms of this letter by signing, dating and returning a copy thereof. |
5. | This letter may be executed in any number of counterparts and this has the same effect as if the signatures on the counterparts were on a single copy of this letter. |
6. | This letter is a Finance Document. |
Barclays Bank PLC Authorised by the Prudential Regulation Authority and regulated by the financial Conduct Authority and the Prudential Regulation Authority.
Registered in England. Registered No. 1026167. Registered office: 1 Churchill Place. London E14 SHP
7. | The provisions of Clause 46 ( Governing law ) and Clause 47 ( Enforcement ) are incorporated into this letter as though they were set out in full, except that references to the Facilities Agreement are to be construed as references to this letter. |
Yours faithfully
/s/ Nick Williams
……………………………
for and on behalf of
Barclays Bank PLC
as Facility Agent, for itself and on behalf of each of the Finance Parties
Acknowledged and agreed
/s/ Jeffrey Poulton
……………………………
for and on behalf of
Shire plc
/s/ Michael Garry
……………………………
for and on behalf of
Shire Acquisitions Investments Ireland DAC
Date: 1 December 2016
APPENDIX 2
SCHEDULE 9
EXISTING SECURITY
Name of
member of the Group |
Security | Total Principal Amount of Indebtedness Secured |
Pharma International Insurance
|
Collateral against letters of credit |
US$ 15,000,000
|
NPS Pharmaceuticals, Inc. |
Security interest in certain patents and intellectual property
|
US$ 81,350,000 |
aPPENDIX 3
Schedule
10
Existing Loans
Name of
member of the Group |
Loan |
Total Principal Amount
s |
Shire Human Genetic Therapies, Inc | Supplier loan |
EUR7,500,000
|
Shire Pharmaceutical Holdings Ireland Limited
|
Supplier loan | EUR12,000,000 |
APPENDIX 4
Schedule
11
Existing Financial Indebtedness
Name of
member of the Group |
Financial Indebtedness |
Total Principal Amount
s |
Pharma International Insurance
|
Counter indemnity obligations related to bank issued letters of credit |
US$ 15,000,000
|
Shire
|
Counter indemnity obligations related to bank issued guarantees
|
Up to EUR 90,000,000
|
Shire HGT Inc. | US property capital lease |
US$ 7,737,000
|
Shire ViroPharma Incorporated | US property capital lease |
US$ 5,255,000
|
NPS Pharmaceuticals, Inc. | Secured non-recourse debt |
US$ 81,350,000
|
Multiple Subsidiaries of the Company |
Uncommitted overdraft and money market lines to the extent drawn
|
Up to US$185,000,000
|
Multiple Subsidiaries of Baxalta Incorporated |
Property capital leases
|
US$ 335,500,000 |
Exhibit 99.3
5 Riverwalk Citywest Business Campus Dublin 24
Ireland
|
|
Deutsche Bank AG, London Branch
Winchester House
1 Great Winchester Street
London, EC2N 2DB
For the attention of: Vikki Adams
8 November 2016
CONSENT REQUEST
Shire PLC- US$5,600,000,000 Term Facilities Agreement dated 2 November 2015
1. | Introduction |
1.1 | We refer to the US$5,600,000,000 term facilities agreement dated 2 November 2015 between, among others, Shire plc (the “ Company ”) as an Original Borrower and an Original Guarantor and Deutsche Bank AG, London Branch as Agent (the “ Facilities Agreement ”). |
1.2 | Save as otherwise defined in this letter, terms and expressions defined in the Facilities Agreement shall have the same meanings when used in this letter and references to Clauses in this letter are references to the relevant clauses of the Facilities Agreement. |
1.3 | We are writing to you in your capacity as Agent pursuant to and in accordance with Clause 38.1 ( Required consents ) to request that the Majority Lenders consent to the amendments described in paragraph 2 of this letter, such amendments to become effective immediately upon the Agent delivering to the Company a signed notice in the form set out in Appendix 1 ( Form of Request Approval Notice ) (a “ Request Approval Notice ”) and the Obligors accepting such Request Approval Notice by signing, dating, and returning a copy thereof to the Agent. |
2. | Requests |
We hereby request that:
(A) | Schedule 9 of the Facilities Agreement be amended to reflect the changes shown in the redline set out in Appendix 2 ( Schedule 9 Existing Security ); and |
(B) | Schedule 11 of the Facilities Agreement be amended to reflect the changes shown in the redline set out in Appendix 3 ( Schedule 11 Existing Financial Indebtedness ), |
(together the “ Requested Amendments ”).
Shire plc
Incorporated and registered in Jersey No. 99854
Registered Office: 22 Grenville Street, St Helier, Jersey JE4 8PX
Correspondence Address: 5 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
3. | Timing of consents |
3.1 | A response is requested by 5:00 pm on 16 November 2016 (the “ Request Deadline ”). |
If, by the Request Deadline, Majority Lenders have provided their consent to the Requested Amendments the Agent shall deliver to the Company a Request Approval Notice.
3.2 | If, by the Request Deadline, the Agent has not delivered to the Company a Request Approval Notice, the Company reserves the right to extend the Request Deadline or, after the expiry of the Request Deadline (whether or not extended), to re-open this consent request (and, if necessary or desirable, amend the content of this consent request) and set a new deadline. |
4. | Miscellaneous |
By providing a Request Approval Notice, you agree in your capacity as Agent that this letter is a Finance Document for the purposes of the Facilities Agreement.
5. | Governing Law and Enforcement |
The provisions of Clause 42 ( Governing law ) and Clause 43 ( Enforcement ) are incorporated into this letter as though they were set out in full, except that references to the Facilities Agreement are to be construed as references to this letter.
Yours faithfully
/s/ Jeffrey Poulton
………………………………
for and on behalf of
Shire plc
Exhibit 99.4
|
|
PRIVATE AND CONFIDENTIAL
Shire plc (the “
Company
”)
5 Riverwalk
Citywest Business Campus
Dublin 24
Ireland
For the attention of: Thomas Greene
16th November 2016
SHIRE PLC – CONSENT REQUEST
1. | We refer to: |
(A) | the term facilities agreement dated 2 November 2015 between, among others, Shire plc as an Original Borrower and an Original Guarantor and Deutsche Bank AG, London Branch as Agent (the “Facilities Agreement”); and |
(B) | your letter to us dated 8 November 2016 in which you requested that the Majority Lenders consent to certain amendments to schedule 9 ( Existing Security ) and to schedule 11 ( Existing Financial Indebtedness ) of the Facilities Agreement (the “ Consent Request ”). |
2. | Unless otherwise defined, terms and expressions defined in the Facilities Agreement or in the Consent Request shall have the same meanings when used in this letter and references to Clauses in this letter are references to the relevant clauses of the Facilities Agreement. |
3. | We confirm that we have received the consent of the Majority Lenders to the Requested Amendments and consequently that the Requested Amendments shall, provided that you and the other Obligor sign, date and return to us a copy of this letter in accordance with paragraph 1.3 of the Consent Request become effective immediately and automatically, and from that date the Facilities Agreement and the Consent Request shall be read and construed as one document. |
4. | Please confirm your agreement to the terms of this letter by signing, dating and returning a copy thereof. |
5. | This letter may be executed in any number of counterparts and this has the same effect as if the signatures on the counterparts were on a single copy of this letter. |
6. | This letter is a Finance Document. |
Chairman of the Supervisory Board: Paul Achleitner.
Management Board: John Cryan (Chairman), Kimberly Hammonds, Stuart Lewis, Sylvie Matherat, Garth Ritchie, Karl von Rohr, Marcus Schenck, Christian Sewing, Werner Steinmuller, Jeffrey Urwin.
Deutsche Bank AG is authorised under German Banking Law (competent authority: European Central Bank and the Ba Fin, Germany's Federal Financial Supervisory Authority) and, in the United Kingdom, by the Prudential Regulation Authority. It is subject to supervision by the European Central Bank and by the BaFin, and is subject to limited regulation in the United Kingdom by the Financial Conduct Authority and the Prudential Regulation Authority.
|
Deutsche Bank AG is a joint stock corporation with limited liability incorporated in the Federal Republic of Germany, Local Court of Frankfurt am Main, HRB No. 30 000; Branch Registration in England and Wales BR000005 and Registered Address: Winchester House, 1 Great Winchester Street, London EC2N 2DB. Deutsche Bank AG, London Branch is a member of the London Stock Exchange. (Details about the extent of our authorisation and regulation in the United Kingdom are available on request or from www.db.com/en/content/eu_disclosures.htm)
|
7. | The provisions of Clause 42 ( Governing law ) and Clause 43 ( Enforcement ) are incorporated into this letter as though they were set out in full, except that references to the Facilities Agreement are to be construed as references to this letter. |
Yours faithfully
/s/ Rajeev Thakeria, /s/ Vikki Adams
……………………………
for and on behalf of
Deutsche Bank AG, London Branch
as Agent, for itself and on behalf of each of the Finance Parties
Acknowledged and agreed
/s/ Jeffrey Poulton
……………………………
for and on behalf of
Shire plc
/s/ Michael Garry
……………………………
for and on behalf of
Shire Acquisitions Investments Ireland DAC
Date: 1 December 2016
APPENDIX 2
SCHEDULE 9
EXISTING SECURITY
Name of
member of the Group |
Security | Total Principal Amount of Indebtedness Secured |
Pharma International Insurance
|
Collateral against letters of credit |
US$ 15,000,000
|
NPS Pharmaceuticals, Inc. |
Security interest in certain patents and intellectual property
|
US$ 81,350,000 |
APPENDIX 3
Schedule 11
Existing Financial Indebtedness
Name of
member of the Group |
Financial Indebtedness |
Total Principal Amount
of Existing Financial Indebtedness |
Pharma International Insurance
|
Counter indemnity obligations related to bank issued letters of credit |
US$ 15,000,000
|
|
|
|
Shire Global Finance/Shire Italia S.p.A ./ Shire Pharmaceutical Holdings Ireland Limited |
Counter indemnity obligations related to bank issued guarantees
|
Up to EUR 90,000,000
|
Shire Human Genetic Therapies, Inc. | US property capital lease |
US$ 7,629,000
|
Shire ViroPharma Incorporated | US property capital lease |
US$ 5,255,000
|
NPS Pharmaceuticals, Inc. | Secured non-recourse debt |
US$ 81,350,000
|
Multiple Subsidiaries of the Company |
Uncommitted overdraft and money market lines to the extent drawn
|
Up to US$185,000,000 |
Multiple Subsidiaries of Baxalta Incorporated |
Property capital leases
|
US$ 335,500,000 |